DK0699686T3 - Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid - Google Patents

Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid

Info

Publication number: DK0699686T3
Authority: DK; Denmark
Prior art keywords: glucagon; insulinotropic peptide; biologically active; active fragments; polypeptides
Prior art date: 1994-08-30

Application number

DK95305963T

Other languages

English (en)

Inventor

William Terry Johnson

Fatima Emitsela Yakubu-Madus

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-30

Filing date

1995-08-25

Publication date

2004-02-16

1995-08-25 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2004-02-16 Application granted granted Critical

2004-02-16 Publication of DK0699686T3 publication Critical patent/DK0699686T3/da

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
230000002473 insulinotropic effect Effects 0.000 title abstract 2
239000012634 fragment Substances 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
229920001184 polypeptide Polymers 0.000 abstract 2
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
102400000321 Glucagon Human genes 0.000 abstract 1
108060003199 Glucagon Proteins 0.000 abstract 1
102000004877 Insulin Human genes 0.000 abstract 1
108090001061 Insulin Proteins 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 abstract 1
229960004666 glucagon Drugs 0.000 abstract 1
230000004190 glucose uptake Effects 0.000 abstract 1
229940125396 insulin Drugs 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

DK95305963T 1994-08-30 1995-08-25 Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid DK0699686T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/297,731 US5574008A (en)	1994-08-30	1994-08-30	Biologically active fragments of glucagon-like insulinotropic peptide

Publications (1)

Publication Number	Publication Date
DK0699686T3 true DK0699686T3 (da)	2004-02-16

Family

ID=23147523

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95305963T DK0699686T3 (da)	1994-08-30	1995-08-25	Biologisk aktive fragmenter af glukagon-lignende insulinotropisk peptid

Country Status (10)

Country	Link
US (1)	US5574008A (da)
EP (1)	EP0699686B1 (da)
AT (1)	ATE251642T1 (da)
AU (1)	AU3372595A (da)
DE (1)	DE69531889T2 (da)
DK (1)	DK0699686T3 (da)
ES (1)	ES2208666T3 (da)
PT (1)	PT699686E (da)
SI (1)	SI0699686T1 (da)
WO (1)	WO1996006628A1 (da)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
US6849708B1 (en)	1986-05-05	2005-02-01	The General Hospital Corporation	Insulinotropic hormone and uses thereof
US7138486B2 (en) *	1986-05-05	2006-11-21	The General Hospital Corporation	Insulinotropic hormone derivatives and uses thereof
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6284727B1 (en)	1993-04-07	2001-09-04	Scios, Inc.	Prolonged delivery of peptides
DE69740096D1 (de)	1996-08-08	2011-02-17	Amylin Pharmaceuticals Inc	Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
JP4798814B2 (ja)	1997-01-07	2011-10-19	アミリン・ファーマシューティカルズ，インコーポレイテッド	食物摂取低減用のエキセンジンおよびそのアゴニストの使用
US5846937A (en) *	1997-03-03	1998-12-08	1149336 Ontario Inc.	Method of using exendin and GLP-1 to affect the central nervous system
US7157555B1 (en)	1997-08-08	2007-01-02	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
US7223725B1 (en)	1997-11-14	2007-05-29	Amylin Pharmaceuticals, Inc.	Exendin agonist compounds
NZ504258A (en)	1997-11-14	2002-12-20	Amylin Pharmaceuticals Inc	Exendin 3 and 4 agonist compounds for the treatment of diabetes
US6703359B1 (en)	1998-02-13	2004-03-09	Amylin Pharmaceuticals, Inc.	Inotropic and diuretic effects of exendin and GLP-1
KR100637433B1 (ko) *	2004-05-24	2006-10-20	삼성에스디아이 주식회사	발광 표시 장치
JP2002508162A (ja) *	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
AU5027299A (en)	1998-07-31	2000-02-28	Novo Nordisk A/S	Use of glp-1 and analogues for preventing type ii diabetes
US6720407B1 (en) *	1998-08-28	2004-04-13	Eli Lilly And Company	Method for administering insulinotropic peptides
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
US6429197B1 (en)	1998-10-08	2002-08-06	Bionebraska, Inc.	Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
EP1137667B1 (en)	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues of glp-1
US7258869B1 (en)	1999-02-08	2007-08-21	Alza Corporation	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en)	1999-02-08	2011-04-05	Intarcia Therapeutics, Inc.	Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US6451987B1 (en)	1999-03-15	2002-09-17	Novo Nordisk A/S	Ion exchange chromatography of proteins and peptides
AU3273200A (en)	1999-03-15	2000-10-04	Novo Nordisk A/S	Ion exchange chromatographic separation of glp-1 and related peptides
US6444788B1 (en)	1999-03-15	2002-09-03	Novo Nordisk A/S	Ion exchange chromatography of GLP-1, analogs and derivatives thereof
US6605648B1 (en) *	1999-04-06	2003-08-12	Phillips Plastics Corporation	Sinterable structures and method
PT1180121E (pt)	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
US20090175821A1 (en) *	1999-05-17	2009-07-09	Bridon Dominique P	Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en)	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
ES2395096T3 (es)	1999-06-29	2013-02-08	Mannkind Corporation	Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US6844321B2 (en)	2000-01-31	2005-01-18	Novo Nordisk A/S	Crystallization of a GLP-1 analogue
ATE309818T1 (de)	2000-03-08	2005-12-15	Novo Nordisk As	Senkung des serum cholesterols
US6926898B2 (en)	2000-04-12	2005-08-09	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2002043709A1 (fr)	2000-12-01	2002-06-06	Takeda Chemical Industries, Ltd.	Procede de production d'une preparation contenant une substance bioactive
WO2002085406A1 (en) *	2001-04-24	2002-10-31	Restoragen, Inc.	Methods and compositions for treating conditions associated with insulin resistance
EP1411968B1 (en) *	2001-07-31	2008-09-17	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Glp-1 exendin-4 peptide analogs and uses thereof
US6642003B2 (en)	2001-08-02	2003-11-04	Cedars-Sinai Medical Center	Human glucose-dependent insulin-secreting cell line
CA2841097A1 (en)	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin and g-csf fusion proteins
WO2003059934A2 (en) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
US7141240B2 (en) *	2002-03-12	2006-11-28	Cedars-Sinai Medical Center	Glucose-dependent insulin-secreting cells transfected with a nucleotide sequence encoding GLP-1
JP4681231B2 (ja)	2002-03-20	2011-05-11	マンカインドコーポレイション	吸入装置
US20080260838A1 (en) *	2003-08-01	2008-10-23	Mannkind Corporation	Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040209803A1 (en) *	2002-12-19	2004-10-21	Alain Baron	Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) *	2002-12-17	2010-09-07	Amylin Pharmaceuticals, Inc.	Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en)	2003-11-17	2010-06-08	Intarcia Therapeutics, Inc.	Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7530968B2 (en)	2003-04-23	2009-05-12	Valeritas, Inc.	Hydraulically actuated pump for long duration medicament administration
US8008255B2 (en)	2003-05-30	2011-08-30	Amylin Pharmaceuticals, Inc.	Methods and compositions for enhanced transmucosal delivery of peptides and proteins
PL1664108T3 (pl)	2003-08-21	2010-03-31	Novo Nordisk As	Rozdzielanie polipeptydów zawierających racemizowany aminokwas
US20070275877A1 (en) *	2003-08-29	2007-11-29	Amylin Pharmaceuticals, Inc.	Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
KR101243648B1 (ko)	2003-11-20	2013-03-14	노보 노르디스크 에이/에스	제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
WO2005056036A2 (en)	2003-12-09	2005-06-23	Novo Nordisk A/S	Regulation of food preference using glp-1 agonists
US20080194483A1 (en) *	2003-12-12	2008-08-14	Brownlee Michael A	GLP-1 (9-36) methods and compositions
EP1701731A4 (en) *	2003-12-12	2009-08-05	Einstein Coll Med	GLP-1 (9-36) METHOD AND COMPOSITIONS
EP1711523B1 (en)	2003-12-16	2012-10-10	Ipsen Pharma	Analogues of glp-1
JP2007514752A (ja)	2003-12-16	2007-06-07	ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス	Ｇｌｐ−１医薬組成物
CN102816241B (zh) *	2004-02-09	2015-07-22	人类基因科学公司	清蛋白融合蛋白
ES2347902T3 (es) *	2004-04-23	2010-11-22	Conjuchem Biotechnologies Inc. Canadian Corporation 4528590	Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US20090069226A1 (en) *	2004-05-28	2009-03-12	Amylin Pharmaceuticals, Inc.	Transmucosal delivery of peptides and proteins
US8410047B2 (en)	2004-06-11	2013-04-02	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
US9089636B2 (en)	2004-07-02	2015-07-28	Valeritas, Inc.	Methods and devices for delivering GLP-1 and uses thereof
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
HUE025151T2 (en)	2004-08-23	2016-01-28	Mannkind Corp	Diceto-piperazine salts for drug delivery
DE102004043153B4 (de) *	2004-09-03	2013-11-21	Philipps-Universität Marburg	Erfindung betreffend GLP-1 und Exendin
WO2006083761A2 (en)	2005-02-03	2006-08-10	Alza Corporation	Solvent/polymer solutions as suspension vehicles
US11246913B2 (en)	2005-02-03	2022-02-15	Intarcia Therapeutics, Inc.	Suspension formulation comprising an insulinotropic peptide
MX373000B (es)	2005-09-14	2020-05-21	Mannkind Corp	Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8039432B2 (en)	2005-11-09	2011-10-18	Conjuchem, Llc	Method of treatment of diabetes and/or obesity with reduced nausea side effect
US20090162345A1 (en) *	2005-11-29	2009-06-25	Atkinson Mark A	Materials and Methods for Reversing Type-1 Diabetes
WO2007075534A2 (en)	2005-12-16	2007-07-05	Nektar Therapeutics Al, Corporation	Polymer conjugates of glp-1
ATE507235T1 (de) *	2006-02-08	2011-05-15	Lonza Ag	Synthese von glucagon-ähnlichen peptiden
CN104383546B (zh)	2006-02-22	2021-03-02	曼金德公司	用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
CN103239773B (zh)	2006-03-30	2015-08-26	瓦莱里塔斯公司	多筒式流体递送器械
EP2020990B1 (en)	2006-05-30	2010-09-22	Intarcia Therapeutics, Inc	Two-piece, internal-channel osmotic delivery system flow modulator
PL2359808T3 (pl)	2006-08-09	2013-10-31	Intarcia Therapeutics Inc	Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en)	2007-04-23	2013-01-16	Intarcia Therapeutics, Inc	Suspension formulations of insulinotropic peptides and uses thereof
EP2578677A1 (en)	2007-08-09	2013-04-10	Genzyme Corporation	Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) *	2007-09-30	2014-06-24	University Of Florida Research Foundation, Inc.	Combination therapies for treating type 1 diabetes
KR20100090692A (ko) *	2007-10-24	2010-08-16	맨카인드 코포레이션	활성제의 전달
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
KR101736502B1 (ko) *	2007-10-24	2017-05-16	맨카인드 코포레이션	Ｇｌｐ-1에 의한 유해 효과의 예방 방법
JP2011506442A (ja) *	2007-12-11	2011-03-03	コンジュケムバイオテクノロジーズインコーポレイテッド	インスリン分泌性ペプチド結合体の製剤
EP2240155B1 (en)	2008-02-13	2012-06-06	Intarcia Therapeutics, Inc	Devices, formulations, and methods for delivery of multiple beneficial agents
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
MY155524A (en)	2008-06-13	2015-10-30	Mannkind Corp	A dry powder inhaler and system for drug delivery
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
DK2344519T3 (da)	2008-11-07	2017-01-23	Massachusetts Gen Hospital	C-terminale fragmenter af glucagonlignende peptid-1 (glp-1)
US9441028B2 (en)	2008-12-08	2016-09-13	Novo Nordisk A/S	Counter current purification of polypeptides
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
US8538707B2 (en)	2009-03-11	2013-09-17	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
AU2010259943C1 (en)	2009-06-12	2016-03-03	Mannkind Corporation	Diketopiperazine microparticles with defined specific surface areas
EP3323423B1 (en)	2009-09-28	2020-06-17	Intarcia Therapeutics, Inc	Rapid establishment and/or termination of substantial steady-state drug delivery
JP5784622B2 (ja)	2009-11-03	2015-09-24	マンカインドコーポレ−ション	吸入活動をシミュレートするための装置及び方法
CN102770152B (zh)	2009-11-25	2016-07-06	阿瑞斯根股份有限公司	肽类的粘膜递送
US9168288B2 (en)	2010-04-09	2015-10-27	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
CA2797033C (en)	2010-04-22	2021-10-19	Longevity Biotech, Inc.	Highly active polypeptides and methods of making and using the same
RU2531455C2 (ru)	2010-06-21	2014-10-20	Маннкайнд Корпорейшн	Системы и способы доставки сухих порошковых лекарств
EP2588490B1 (en)	2010-07-02	2017-02-22	Angiochem Inc.	Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
WO2012054822A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Pharmacologically active polymer-glp-1 conjugates
WO2012054861A1 (en)	2010-10-22	2012-04-26	Nektar Therapeutics	Glp-1 polymer conjugates having a releasable linkage
US9040481B2 (en)	2010-11-02	2015-05-26	The General Hospital Corporation	Methods for treating steatotic disease
US20120208755A1 (en)	2011-02-16	2012-08-16	Intarcia Therapeutics, Inc.	Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
MX353285B (es)	2011-04-01	2018-01-05	Mannkind Corp	Paquete de blister para cartuchos farmaceuticos.
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
EP2729157B1 (en)	2011-07-06	2019-01-16	The General Hospital Corporation	A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
HK1201475A1 (en)	2011-10-24	2015-09-04	Mannkind Corporation	Methods and compositions for treating pain
MX2014015557A (es)	2012-06-21	2015-02-24	Univ Indiana Res & Tech Corp	Polipeptidos de fusion de region fc de polipeptido de ligando receptor de incretina y conjugados con función efectora fc alterada.
US20150157619A1 (en)	2012-07-10	2015-06-11	Takeda Pharmaceutical Company Limited	Pharmaceutical preparation for injection
AU2013289957B2 (en)	2012-07-12	2017-02-23	Mannkind Corporation	Dry powder drug delivery systems and methods
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
BR112015023168B1 (pt)	2013-03-15	2021-08-10	Mannkind Corporation	Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
WO2014145718A2 (en)	2013-03-15	2014-09-18	Longevity Biotech, Inc.	Peptides comprising non-natural amino acids and methods of making and using the same
BR122019026637B1 (pt)	2013-07-18	2023-09-26	Mannkind Corporation	Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
CA2920488C (en)	2013-08-05	2022-04-26	Mannkind Corporation	Insufflation apparatus and methods
US10137170B2 (en)	2013-12-20	2018-11-27	Indiana University Research And Technology Corporation	Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
CN104267194B (zh) *	2014-09-23	2016-01-13	上海市东方医院	人胰高血糖素样肽-1、抗体及其试剂盒
US9889085B1 (en)	2014-09-30	2018-02-13	Intarcia Therapeutics, Inc.	Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
ES2968262T3 (es)	2015-06-03	2024-05-08	I2O Therapeutics Inc	Sistemas de colocación de implantes
KR20240037175A (ko)	2016-05-16	2024-03-21	인타르시아 세라퓨틱스 인코포레이티드	글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en)	2016-06-02	2019-09-17	Intarcia Therapeutics, Inc.	Implant removal tool
USD840030S1 (en)	2016-06-02	2019-02-05	Intarcia Therapeutics, Inc.	Implant placement guide
AU2018206539A1 (en)	2017-01-03	2019-07-18	Intarcia Therapeutics, Inc.	Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
BR112020002804A2 (pt)	2017-08-24	2020-07-28	Novo Nordisk A/S	composição farmacêutica líquida, e, kit
AU2019357621B2 (en)	2018-10-11	2025-04-03	Intarcia Therapeutics, Inc.	Human amylin analog polypeptides and methods of use
IL294521A (en)	2020-02-18	2022-09-01	Novo Nordisk As	glp-1 compounds and their uses
CA3223596A1 (en) *	2021-06-29	2023-01-05	Thomas A. GILL	Peptides for regulating glucose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ202757A (en) *	1981-12-23	1985-11-08	Novo Industri As	Peptides and medicaments
US4710473A (en)	1983-08-10	1987-12-01	Amgen, Inc.	DNA plasmids
US5120712A (en) *	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
US5118666A (en) *	1986-05-05	1992-06-02	The General Hospital Corporation	Insulinotropic hormone
JP2583257B2 (ja) *	1986-05-05	1997-02-19	ザ・ジェネラル・ホスピタル・コーポレーション	インシュリン向性ホルモン
US4923967A (en)	1988-09-26	1990-05-08	Eli Lilly And Company	Purification and refolding of recombinant proteins
ATE193541T1 (de) *	1989-03-20	2000-06-15	Gen Hospital Corp	Insulinotropes hormon
ES2113879T3 (es) *	1990-01-24	1998-05-16	Douglas I Buckley	Analogos de glp-1 utiles para el tratamiento de diabetes.
DK36392D0 (da) *	1992-03-19	1992-03-19	Novo Nordisk As	Anvendelse af kemisk forbindelse
BR9306551A (pt) *	1992-06-15	1998-09-15	Pfizer	Derivados de peptídeo do tipo glucagona e de insulinotropina
NZ250844A (en) *	1993-04-07	1996-03-26	Pfizer	Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use

1994
- 1994-08-30 US US08/297,731 patent/US5574008A/en not_active Expired - Fee Related
1995
- 1995-08-25 DE DE69531889T patent/DE69531889T2/de not_active Expired - Fee Related
- 1995-08-25 EP EP95305963A patent/EP0699686B1/en not_active Expired - Lifetime
- 1995-08-25 AT AT95305963T patent/ATE251642T1/de not_active IP Right Cessation
- 1995-08-25 ES ES95305963T patent/ES2208666T3/es not_active Expired - Lifetime
- 1995-08-25 WO PCT/US1995/010793 patent/WO1996006628A1/en not_active Ceased
- 1995-08-25 AU AU33725/95A patent/AU3372595A/en not_active Abandoned
- 1995-08-25 DK DK95305963T patent/DK0699686T3/da active
- 1995-08-25 PT PT95305963T patent/PT699686E/pt unknown
- 1995-08-25 SI SI9530684T patent/SI0699686T1/xx unknown

Also Published As

Publication number	Publication date
EP0699686A3 (en)	1996-10-16
SI0699686T1 (en)	2004-02-29
ES2208666T3 (es)	2004-06-16
DE69531889T2 (de)	2004-07-22
WO1996006628A1 (en)	1996-03-07
EP0699686B1 (en)	2003-10-08
EP0699686A2 (en)	1996-03-06
DE69531889D1 (de)	2003-11-13
US5574008A (en)	1996-11-12
AU3372595A (en)	1996-03-22
ATE251642T1 (de)	2003-10-15
PT699686E (pt)	2004-02-27

Publication	Publication Date	Title
DE69531889D1 (de)	2003-11-13	Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
ATE193541T1 (de)	2000-06-15	Insulinotropes hormon
ATE285473T1 (de)	2005-01-15	Glucagon-ähnliche insulinotrope peptid-analoge, zusammensetzungen und verwendungsverfahren
ATE164852T1 (de)	1998-04-15	Glp-1-analoga verwendbar in der diabetesbehandlung
GEP20063908B (en)	2006-08-25	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
ATE480259T1 (de)	2010-09-15	Intranasale verabreichung von glucose- regulierenden peptiden
DE60228972D1 (de)	2008-10-30	Glp 1 exendin 4 peptidanaloga und deren verwendungen
BR9710452A (pt)	1999-08-17	Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
DK1171465T3 (da)	2004-12-13	Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
PE20011363A1 (es)	2002-01-15	Analogos del peptido-1 semejante a glucagon
AR022368A1 (es)	2002-09-04	Procedimiento para administrar peptidos insulinotropicos
GB2431583A (en)	2007-05-02	Combination therapy using transferrin fusion proteins comprising GLP-1
HUT68525A (en)	1995-06-28	Pharmaceutical compositions of prolonged delivery, containing peptides
TR200000649T2 (tr)	2000-09-21	PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
DE60039111D1 (de)	2008-07-17	Agonisten des rezeptors 3 (r3) von pituitary adenylate cyclase aktivierendem peptid (pacap) und ihre pharmakologische verwendung
WO2004094461A3 (en)	2005-09-15	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
DE69327309D1 (de)	2000-01-20	Verwendung eines peptids
DK0470117T3 (da)	1994-03-14	Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ES2087337T3 (es)	1996-07-16	Composiciones de implantes que contienen una proteina, peptido o polipeptido biologicamente activos.
ECSP951557A (es)	1997-07-28	Analogos composiciones y procedimientos de uso de peptidos insulinotropicos similares al glucagon
ECSP993116A (es)	1999-11-29	Procedimiento para administrar peptidos insulinotropicos
AR005791A1 (es)	1999-07-14	Proteina de hormona del crecimiento humano mutante; desoxirribo-nucleotido que la codifica; peptido de dicha proteina; plasmido de expresion deldesoxirribonucleotido; producto generado por las celulas transformadas por el anterior; anticuerpo y medicamento que contiene la proteina o el